Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (October 2021)
15 slides from Neurotech International's investor presentation, Oct 25, 2021
Slide 1: Investor Webinar Presentation October 2021
For personal use only Investor Webinar Presentation October 2021 BRIDGING TO A BETTER LIFE Neurotech International Limited (ASX: NTI)
Slide 2: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 3: Unique Value Proposition
Unique Value Proposition For personal use only $ THC Neurotech is focussed on Neurotech has exclusive worldwide Dolce Cann Global cannabis Potential for the the development & licence to utilise proprietary strains contain naturally low NTI/Dolce cannabis commercialisation of cannabis strains from Do
Slide 4: Corporate Overview
Corporate Overview For personal use only CAPITAL STRUCTURE Share price $0.05 (as at 22 October 2021) Shares on issue 696m Options 113m^ Cash at bank* ~$4.83m Market capitalisation ~$35m ^Options have various strike prices between $0.005 to $0.09 *As at 30 June 2021 4
Slide 5: Highly Experienced Board
Highly Experienced Board For personal use only Brian Leedman Krista Bates Prof. Allan Cripps AO Mark Davies Winton Willesse Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director • More than 15 years’ • Experienced director of ASX and • Distinguished aca
Slide 6: Medicinal Cannabis industry is only just getting started
Medicinal Cannabis industry is only just getting started For personal use only There are only four approved cannabis based drugs U.S legal marijuana market size, by product type, 2014-2028 (USD Billion FDA • Marinol® (dronabinol) synthetically manufactured (CBD | THC) and registered in the US by the
Slide 7: Global drug market size for neurological disease
Global drug market size for neurological disease For personal use only MULTIPLE EPILEPSY SCLEROSIS 3$US5.5b 1US$20b • Future target • Preclinical studies in TRAUMATIC progress AUTISM BRAIN INJURY • Future Target SPECTRUM 2US$6.8b DISORDER 5$US2.3b • Future target MIGRAINE 4$1.7b • Preclinical comple
Slide 8: NTI/Dolce strains have unique properties compared to CBD alone
NTI/Dolce strains have unique properties compared to CBD alone For personal use only • Very high levels of CBD-A (primary active) – • Preclinical studies have demonstrated that studies have confirmed that CBD-A up to NTI/Dolce strains (<0.3% THC) exhibit 1,000 times more potent in regulating powerfu
Slide 9: Results from Pre-clinical Studies
Results from Pre-clinical Studies For personal use only Key Findings Studies were designed In all studies the top DOLCE/NTI strains demonstrated superiority when compared to CBD alone. to assess the • Reduction in brain cell inflammation (up to 60%) neuroprotective and neuro-modulatory • Increase in
Slide 10: Expected pathway of cannabis project
Expected pathway of cannabis project For personal use only 1. In vitro assay assessments 2. Product formulation and 3. Phase I/II Human safety Neuronal or muscle cell line assessments final dose profiling & efficacy clinical trials Analytical assessments & To be conducted in Commenced in May 2021 in
Slide 11: Why target Autism Spectrum Disorders (ASD)?
Why target Autism Spectrum Disorders (ASD)? For personal use only • ASD is a serious neuro inflammatory developmental disorder that impairs the ability to communicate and interact ➢ Range and severity of symptoms can vary widely ➢ Common symptoms include; behavioural issues, agitation, repetitive mo
Slide 12: Pathways to commercialisation
Pathways to commercialisation The anti-inflammatory properties NTI Dolce strains in combination with minimal presence of THC (< 0.3%) For personal use only provides three clear pathways to commercialisation: 2. Product formulation and 3. Phase I/II Human safety final dose profiling & efficacy clinic
Slide 13: Strategic Partners
Strategic Partners For personal use only Monash Children’s Hospital A/Prof Michael Fahey – Head of Neurology Professor Katrina Harris – Head of Paediatrics 2. Product formulation and Victorian College of Pharmacy final dose profiling Department: Centre for Medicinal Chemistry ACS Laboratories | Melb
Slide 14: Expected news flow
Expected news flow For personal use only 1. 2. 3. 4. 5. 6. New indication Expansion of Preclinical Further Preclinical Interim results on Final results on Large multi-cohort Phase III Phase I/II clinical programme into wider results in MS Phase I/II clinical Phase I/II clinical Registration Trials i
Slide 15: Contact Details
For personal use only C O N TAC T D E TA I LS Brian Leedman Winton Willesee Chairman Non-Executive Director [email protected] [email protected] +61 412 281 780 +61 410 667 844 This presentation has been authorised for release by the Chairman of Neurotech International Limited. www
Neurotech International — Investor Presentation (October 2021) on 6ix